Amira Mohamed Taha , Sara Adel Abdelkader Saed , Mostafa Hossam-Eldin Moawad , Wesam Abd El-Tawab Moawad , Tala Al-hejazi , Yosra Mousa , Ramaswamy Sharma , Russel J. Reiter
{"title":"褪黑素辅助治疗新冠肺炎患者的安全性和有效性：系统综述和荟萃分析。","authors":"Amira Mohamed Taha , Sara Adel Abdelkader Saed , Mostafa Hossam-Eldin Moawad , Wesam Abd El-Tawab Moawad , Tala Al-hejazi , Yosra Mousa , Ramaswamy Sharma , Russel J. Reiter","doi":"10.1016/j.advms.2023.09.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>Melatonin might be beneficial to </span>coronavirus<span> disease 2019 (COVID-19) patients in terms of both prevention and treatment. We investigated how melatonin affected various clinical and laboratory results in COVID-19 patients.</span></p></div><div><h3>Methods</h3><p><span>PubMed, Scopus, </span>Cochrane Library and Web of Science databases were utilized for searching eligible articles fulfilling our inclusion criteria up to December 2022. We used random effect model in case of significant heterogeneity; in other cases, a fixed model was applied. RevMan was used for meta-analysis.</p></div><div><h3>Results</h3><p><span>We included 11 studies in our review. Clinical improvement rate was found to be statistically significantly higher in patients taking melatonin than in the control group (OR: 5.09; 95% CI: 2.60−9.96, p < 0.001). Patients receiving melatonin showed a non-significant difference in mortality rate compared to the control group (OR: 0.37; 95% CI: 0.07−1.81, p = 0.22). However, in the </span>randomized controlled trials<span> subgroup, melatonin-treated patients showed significantly lower mortality than did the controls (OR: 0.17; 95% CI: 0.08−0.38, p < 0.001). CRP level was statistically significantly lower due to melatonin treatment (weighted mean difference [WMD] = −9.85; 95% CI: −18.54 to −1.16, p = 0.03). Length of hospital stay was statistically significantly shorter in patients taking melatonin compared to controls (WMD = −4.05; 95% CI: −5.39 to −2.7, p < 0.001).</span></p></div><div><h3>Conclusion</h3><p><span>Melatonin was found to have substantial effects on COVID-19 patients when used as adjuvant therapy, enhancing clinical improvement and decreasing time to recovery with a shorter length of hospital stay and a shorter duration of </span>mechanical ventilation.</p></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"68 2","pages":"Pages 341-352"},"PeriodicalIF":2.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and efficacy of melatonin as an adjuvant therapy in COVID-19 patients: Systematic review and meta-analysis\",\"authors\":\"Amira Mohamed Taha , Sara Adel Abdelkader Saed , Mostafa Hossam-Eldin Moawad , Wesam Abd El-Tawab Moawad , Tala Al-hejazi , Yosra Mousa , Ramaswamy Sharma , Russel J. Reiter\",\"doi\":\"10.1016/j.advms.2023.09.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><span>Melatonin might be beneficial to </span>coronavirus<span> disease 2019 (COVID-19) patients in terms of both prevention and treatment. We investigated how melatonin affected various clinical and laboratory results in COVID-19 patients.</span></p></div><div><h3>Methods</h3><p><span>PubMed, Scopus, </span>Cochrane Library and Web of Science databases were utilized for searching eligible articles fulfilling our inclusion criteria up to December 2022. We used random effect model in case of significant heterogeneity; in other cases, a fixed model was applied. RevMan was used for meta-analysis.</p></div><div><h3>Results</h3><p><span>We included 11 studies in our review. Clinical improvement rate was found to be statistically significantly higher in patients taking melatonin than in the control group (OR: 5.09; 95% CI: 2.60−9.96, p < 0.001). Patients receiving melatonin showed a non-significant difference in mortality rate compared to the control group (OR: 0.37; 95% CI: 0.07−1.81, p = 0.22). However, in the </span>randomized controlled trials<span> subgroup, melatonin-treated patients showed significantly lower mortality than did the controls (OR: 0.17; 95% CI: 0.08−0.38, p < 0.001). CRP level was statistically significantly lower due to melatonin treatment (weighted mean difference [WMD] = −9.85; 95% CI: −18.54 to −1.16, p = 0.03). Length of hospital stay was statistically significantly shorter in patients taking melatonin compared to controls (WMD = −4.05; 95% CI: −5.39 to −2.7, p < 0.001).</span></p></div><div><h3>Conclusion</h3><p><span>Melatonin was found to have substantial effects on COVID-19 patients when used as adjuvant therapy, enhancing clinical improvement and decreasing time to recovery with a shorter length of hospital stay and a shorter duration of </span>mechanical ventilation.</p></div>\",\"PeriodicalId\":7347,\"journal\":{\"name\":\"Advances in medical sciences\",\"volume\":\"68 2\",\"pages\":\"Pages 341-352\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in medical sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1896112623000342\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in medical sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1896112623000342","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
背景：褪黑激素在预防和治疗方面可能对2019冠状病毒病（新冠肺炎）患者有益。我们研究了褪黑激素如何影响新冠肺炎患者的各种临床和实验室结果。方法：利用PubMed、Scopus、Cochrane Library和Web of Science数据库搜索截至2022年12月符合我们纳入标准的合格文章。在显著异质性的情况下，我们使用随机效应模型；在其他情况下，应用固定模型。RevMan用于荟萃分析。结果：我们在综述中纳入了11项研究。服用褪黑素的患者的临床改善率在统计学上显著高于对照组（OR:5.09；95%CI:2.60-9.96，p结论：褪黑激素作为辅助治疗对新冠肺炎患者有显著作用，可缩短住院时间和机械通气时间，提高临床疗效，缩短康复时间。
Safety and efficacy of melatonin as an adjuvant therapy in COVID-19 patients: Systematic review and meta-analysis
Background
Melatonin might be beneficial to coronavirus disease 2019 (COVID-19) patients in terms of both prevention and treatment. We investigated how melatonin affected various clinical and laboratory results in COVID-19 patients.
Methods
PubMed, Scopus, Cochrane Library and Web of Science databases were utilized for searching eligible articles fulfilling our inclusion criteria up to December 2022. We used random effect model in case of significant heterogeneity; in other cases, a fixed model was applied. RevMan was used for meta-analysis.
Results
We included 11 studies in our review. Clinical improvement rate was found to be statistically significantly higher in patients taking melatonin than in the control group (OR: 5.09; 95% CI: 2.60−9.96, p < 0.001). Patients receiving melatonin showed a non-significant difference in mortality rate compared to the control group (OR: 0.37; 95% CI: 0.07−1.81, p = 0.22). However, in the randomized controlled trials subgroup, melatonin-treated patients showed significantly lower mortality than did the controls (OR: 0.17; 95% CI: 0.08−0.38, p < 0.001). CRP level was statistically significantly lower due to melatonin treatment (weighted mean difference [WMD] = −9.85; 95% CI: −18.54 to −1.16, p = 0.03). Length of hospital stay was statistically significantly shorter in patients taking melatonin compared to controls (WMD = −4.05; 95% CI: −5.39 to −2.7, p < 0.001).
Conclusion
Melatonin was found to have substantial effects on COVID-19 patients when used as adjuvant therapy, enhancing clinical improvement and decreasing time to recovery with a shorter length of hospital stay and a shorter duration of mechanical ventilation.
期刊介绍：
Advances in Medical Sciences is an international, peer-reviewed journal that welcomes original research articles and reviews on current advances in life sciences, preclinical and clinical medicine, and related disciplines.
The Journal’s primary aim is to make every effort to contribute to progress in medical sciences. The strive is to bridge laboratory and clinical settings with cutting edge research findings and new developments.
Advances in Medical Sciences publishes articles which bring novel insights into diagnostic and molecular imaging, offering essential prior knowledge for diagnosis and treatment indispensable in all areas of medical sciences. It also publishes articles on pathological sciences giving foundation knowledge on the overall study of human diseases. Through its publications Advances in Medical Sciences also stresses the importance of pharmaceutical sciences as a rapidly and ever expanding area of research on drug design, development, action and evaluation contributing significantly to a variety of scientific disciplines.
The journal welcomes submissions from the following disciplines:
General and internal medicine,
Cancer research,
Genetics,
Endocrinology,
Gastroenterology,
Cardiology and Cardiovascular Medicine,
Immunology and Allergy,
Pathology and Forensic Medicine,
Cell and molecular Biology,
Haematology,
Biochemistry,
Clinical and Experimental Pathology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
